|
Delayed
NSE India S.E.
11:45:14 01/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 5,287.00 INR | -0.80% |
|
-1.19% | -4.00% |
| 08-14 | Alkem Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 | |
| 08-14 | Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 432,909 | 406,055 | 590,890 | 583,680 | 633,575 | 637,222 | - | - |
| Change | - | -6.2% | 45.52% | -1.22% | 8.55% | 0.58% | - | - |
| Enterprise Value (EV) 1 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 624,142 | 609,163 | 600,361 |
| Change | - | -9.21% | 49.1% | -1.46% | 9.3% | -1.32% | -2.4% | -1.45% |
| P/E | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 27.8x | 24.1x | 20.8x |
| PBR | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 4.12x | 3.64x | 3.21x |
| PEG | - | -1x | 0.4x | 1.3x | 4.37x | -95.34x | 1.6x | 1.3x |
| Capitalization / Revenue | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.82x | 3.43x | 3.11x |
| EV / Revenue | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.74x | 3.28x | 2.93x |
| EV / EBITDA | 21.1x | 24.5x | 26.2x | 23x | 21x | 18.2x | 15.5x | 13.5x |
| EV / EBIT | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 21x | 17.8x | 15.4x |
| EV / FCF | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 60.7x | 29.8x | 23.5x |
| FCF Yield | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 1.65% | 3.36% | 4.25% |
| Dividend per Share 2 | 34 | 25 | 40 | 45 | 53 | 49.33 | 55.28 | 63.37 |
| Rate of return | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 0.93% | 1.04% | 1.19% |
| EPS 2 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 191.9 | 220.7 | 256 |
| Distribution rate | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 25.7% | 25% | 24.8% |
| Net sales 1 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 166,997 | 185,721 | 204,703 |
| EBITDA 1 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,213 | 39,286 | 44,365 |
| EBIT 1 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,727 | 34,232 | 39,074 |
| Net income 1 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,143 | 27,153 | 31,030 |
| Net Debt 1 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -13,079 | -28,058 | -36,861 |
| Reference price 2 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,299.00 | 5,329.50 | 5,329.50 | 5,329.50 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 5/13/22 A | 5/19/23 A | 5/29/24 A | 5/29/25 A | 5/28/26 A | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.77x | 3.74x | 18.24x | 0.93% | 6.7B | |
| 32.93x | 11.96x | 24.23x | 0.6% | 1,031B | |
| 29.57x | - | - | 2.02% | 641B | |
| 32.73x | 7.6x | 15.79x | 2.67% | 453B | |
| 19.66x | 4.67x | 11.58x | 2.83% | 349B | |
| 21.66x | 5.59x | 13.87x | 2.87% | 290B | |
| 20.88x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.19x | 7.03x | 12.5x | 2.35% | 232B | |
| 13.11x | 4.72x | 9.86x | 3.87% | 201B | |
| -44.72x | 6.46x | 25.22x | 2.25% | 181B | |
| Average | 18.08x | 6.23x | 15.95x | 2.24% | 363.65B | |
| Weighted average by Cap. | 23.96x | 7.97x | 17.65x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
